ABIVAX

7-11 Boulevard Haussmann
75009 Paris
France

Contact

About ABIVAX

ABIVAX is a leading clinical stage biotech company focused on becoming a global leader in the discovery, development and commercialisation of anti-viral compounds and human vaccines to treat some of the world’s most important infectious diseases, including HIV/AIDS and Hepatitis B.

News about ABIVAX

02-Jan-2025 | people

Abivax announces a change in the composition of its Board of Directors

Abivax SA announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his resignation as director of the Company effective on ...

Read news

03-Feb-2015 | research and development

Treatment of the first HIV positive patient in ABIVAX’s Phase IIa clinical trial with ABX464

ABIVAX announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464. ABX464 is a novel, ...

Read news

03-Dec-2014 | research and development

ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV

ABIVAX announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of ...

Read news

Show more news about ABIVAX

Get the life science industry in your inbox

ABIVAX

About ABIVAX

News about ABIVAX

Abivax announces a change in the composition of its Board of Directors

Treatment of the first HIV positive patient in ABIVAX’s Phase IIa clinical trial with ABX464

ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV

Here you will find ABIVAX

ABIVAX